$ELDN
Eledon Pharmaceuticals, Inc.

2016 Q3 Form 10-Q Financial Statement

#000119312516672054 Filed on August 04, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.150M $3.680M $3.130M
YoY Change -7.89% 17.57% 110.07%
% of Gross Profit
Research & Development $6.162M $592.0K $5.855M
YoY Change -27.43% -89.89% 33.31%
% of Gross Profit
Depreciation & Amortization $40.00K $60.00K $10.00K
YoY Change 33.33% 500.0% 0.0%
% of Gross Profit
Operating Expenses $9.308M $932.0K $8.982M
YoY Change -21.83% -89.62% 52.63%
Operating Profit -$9.308M -$932.0K -$8.982M
YoY Change -21.83% -89.62% 52.63%
Interest Expense $40.00K $50.00K $30.00K
YoY Change -20.0% 66.67%
% of Operating Profit
Other Income/Expense, Net -$70.00K
YoY Change
Pretax Income -$9.270M -$13.53M -$8.960M
YoY Change -21.77% 51.0% 53.16%
Income Tax
% Of Pretax Income
Net Earnings -$9.270M -$1.002M -$8.957M
YoY Change -21.79% -88.81% 53.08%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$66.21M -$96.64M -$64.00M
COMMON SHARES
Basic Shares Outstanding 22.63M shares 22.63M shares 22.41M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.70M $43.90M $83.20M
YoY Change -52.53% -47.24% 292.45%
Cash & Equivalents $18.63M $12.16M $59.08M
Short-Term Investments $16.10M $31.80M $24.10M
Other Short-Term Assets $1.600M $2.300M $3.600M
YoY Change -57.89% -36.11% 500.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $36.33M $46.19M $86.76M
YoY Change -52.73% -46.76% 299.8%
LONG-TERM ASSETS
Property, Plant & Equipment $117.0K $401.0K $339.0K
YoY Change -72.6% 18.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $300.0K $45.00K
YoY Change 566.67% 566.67% -97.19%
Total Long-Term Assets $387.0K $671.0K $654.0K
YoY Change -47.84% 2.6% -61.53%
TOTAL ASSETS
Total Short-Term Assets $36.33M $46.19M $86.76M
Total Long-Term Assets $387.0K $671.0K $654.0K
Total Assets $36.72M $46.86M $87.41M
YoY Change -52.68% -46.39% 273.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $886.0K $1.846M $1.704M
YoY Change -46.37% 8.33% 42.0%
Accrued Expenses $5.458M $5.971M $2.943M
YoY Change 36.28% 102.89% 17.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.344M $7.817M $4.647M
YoY Change 12.14% 68.22% 25.59%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $200.0K $0.00
YoY Change 0.0%
Other Long-Term Liabilities $13.00K
YoY Change
Total Long-Term Liabilities $120.0K $156.0K $13.00K
YoY Change 135.29% 1100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.344M $7.817M $4.647M
Total Long-Term Liabilities $120.0K $156.0K $13.00K
Total Liabilities $6.464M $7.973M $4.660M
YoY Change 13.24% 71.09% 25.95%
SHAREHOLDERS EQUITY
Retained Earnings -$165.7M -$156.4M -$108.6M
YoY Change 37.57% 44.05%
Common Stock $195.9M $195.3M $191.3M
YoY Change 1.87% 2.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.26M $38.88M $82.75M
YoY Change
Total Liabilities & Shareholders Equity $36.72M $46.86M $87.41M
YoY Change -52.68% -46.39% 273.55%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$9.270M -$1.002M -$8.957M
YoY Change -21.79% -88.81% 53.08%
Depreciation, Depletion And Amortization $40.00K $60.00K $10.00K
YoY Change 33.33% 500.0% 0.0%
Cash From Operating Activities -$9.170M -$10.30M -$11.01M
YoY Change -10.54% -6.45% 103.14%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$140.0K
YoY Change -100.0% -100.0% 1300.0%
Acquisitions
YoY Change
Other Investing Activities $15.65M $8.150M -$24.15M
YoY Change -199.68% -133.75%
Cash From Investing Activities $15.65M $8.150M -$24.29M
YoY Change -198.74% -133.55% 242800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 220.0K
YoY Change -100.0% -100.0% -150.0%
NET CHANGE
Cash From Operating Activities -9.170M -10.30M -11.01M
Cash From Investing Activities 15.65M 8.150M -24.29M
Cash From Financing Activities 0.000 0.000 220.0K
Net Change In Cash 6.480M -2.150M -35.08M
YoY Change -125.01% -93.87% 497.61%
FREE CASH FLOW
Cash From Operating Activities -$9.170M -$10.30M -$11.01M
Capital Expenditures $0.00 $0.00 -$140.0K
Free Cash Flow -$9.170M -$10.30M -$10.87M
YoY Change -9.12% -5.24% 100.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22634825 shares
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59084000
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
934000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22634825 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22634825 shares
CY2016Q2 us-gaap Assets
Assets
46857000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
46186000
CY2016Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
31771000
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
195245000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12156000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
23000
CY2016Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
31765000
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1846000
CY2016Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
468000
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5971000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1608000
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
156000
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2016Q2 us-gaap Liabilities
Liabilities
7973000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46857000
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7817000
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
63000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
280000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
489000
CY2016Q2 us-gaap Investments And Cash
InvestmentsAndCash
43927000
CY2016Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
41810000
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
839000
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
401000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
38884000
CY2016Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156390000
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2259000
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
270000
CY2016Q2 tkai Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
4506000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105256000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
900000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22597144 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22597144 shares
CY2015Q4 us-gaap Assets
Assets
67974000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
67170000
CY2015Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
55000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
39934000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
193194000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24023000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2015Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39989000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1208000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
699000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-55000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51028000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4954000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
88000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Liabilities
Liabilities
6250000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67974000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6162000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
167000
CY2015Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
58295000
us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
49000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
489000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
61724000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131438000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3213000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
270000
CY2015Q4 tkai Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3188000
us-gaap Business Exit Costs1
BusinessExitCosts1
133000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-46172000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.99
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1240000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
135000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5868000
us-gaap Allowance For Loan And Lease Losses Adjustments Net
AllowanceForLoanAndLeaseLossesAdjustmentsNet
49000
us-gaap Depreciation
Depreciation
21000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22219000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
487000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-636000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
13000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000
us-gaap Operating Expenses
OperatingExpenses
22282000
us-gaap Net Income Loss
NetIncomeLoss
-22217000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
24078000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-24340000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2000
us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P30D
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
905000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1307000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
45000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22282000
us-gaap Interest And Other Income
InterestAndOtherIncome
65000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
277000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-22109000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
192000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
70000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16414000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
228000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22403031 shares
tkai Marketable Securities Premium On Securities Purchased
MarketableSecuritiesPremiumOnSecuritiesPurchased
35000
tkai Number Of Milestones Achieved
NumberOfMilestonesAchieved
0 Milestone
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-76000
dei Entity Registrant Name
EntityRegistrantName
TOKAI PHARMACEUTICALS INC
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2945343 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001404281
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11867000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.10
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2014000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7229000
us-gaap Depreciation
Depreciation
105000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24891000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
91000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
347000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1017000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
68000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
61000
us-gaap Operating Expenses
OperatingExpenses
25055000
us-gaap Net Income Loss
NetIncomeLoss
-24952000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
500000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
8133000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
61000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
638000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-999000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25055000
us-gaap Interest And Other Income
InterestAndOtherIncome
103000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-20037000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates, assumptions and judgments reflected in these financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#x2019;s estimates.</p> </div>
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
dei Trading Symbol
TradingSymbol
TKAI
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17826000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
37000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
8650000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22629917 shares
tkai Marketable Securities Premium On Securities Purchased
MarketableSecuritiesPremiumOnSecuritiesPurchased
2000
tkai Earliest Year Open For Tax Examination
EarliestYearOpenForTaxExamination
2012
tkai Increase Decrease In Deferred Tax Assets
IncreaseDecreaseInDeferredTaxAssets
10000000
tkai Number Of Milestones Achieved
NumberOfMilestonesAchieved
0 Milestone
CY2015Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-07-31
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2901964 shares
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
606000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3127000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8959000
CY2015Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
181000
CY2015Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
8982000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-8957000
CY2015Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8982000
CY2015Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
25000
CY2015Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5855000
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22421622 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
992000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3680000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13515000
CY2016Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
174000
CY2016Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
13575000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9895000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-13526000
CY2016Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
11000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13575000
CY2016Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
49000
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22634825 shares

Files In Submission

Name View Source Status
0001193125-16-672054-index-headers.html Edgar Link pending
0001193125-16-672054-index.html Edgar Link pending
0001193125-16-672054.txt Edgar Link pending
0001193125-16-672054-xbrl.zip Edgar Link pending
d222775d10q.htm Edgar Link pending
d222775dex311.htm Edgar Link pending
d222775dex312.htm Edgar Link pending
d222775dex321.htm Edgar Link pending
d222775dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tkai-20160630.xml Edgar Link completed
tkai-20160630.xsd Edgar Link pending
tkai-20160630_cal.xml Edgar Link unprocessable
tkai-20160630_def.xml Edgar Link unprocessable
tkai-20160630_lab.xml Edgar Link unprocessable
tkai-20160630_pre.xml Edgar Link unprocessable